Human Breast Adenocarcinoma Cell MCF7 Transfection Kit
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 0.5 ml(Cat-176586) | Inquiry | Add to cart | |
| 1.5 ml(Cat-176687) | Inquiry | Add to cart | |
| 1.5 ml CRISPR(Cat-216988) | Inquiry | Add to cart | |
| 8.0 ml(Cat-705989) | Inquiry | Add to cart |
Description
Product Information
Modes of administration
Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Description
The MCF7 human breast adenocarcinoma cell line is a highly perplexing model system that has garnered much attention in the field of breast cancer research. Originally derived from a breast tumor of a 69-year-old woman with metastatic breast cancer, MCF7 cells are extensively utilized for investigating a wide array of breast cancer biology aspects. These endeavors encompass the deciphering of molecular mechanisms underlying tumor development and progression, and pinpointing potential therapeutic targets for treating breast cancer.
MCF7 cells are highly bursty and possess several unique properties that make them ideal for research. For instance, they are quite easy to culture in the laboratory and can be grown in large quantities. MCF7 cells also express markers of breast cancer, such as estrogen and progesterone receptors, and display a multitude of characteristics that are specific to breast cancer, including uncontrolled proliferation, invasion, and metastasis.
Moreover, MCF7 cells exhibit a high degree of responsiveness to various stimuli, such as growth factors and hormones, making them a powerful model system for studying the effects of these factors on breast cancer cell growth and survival.
To optimize the efficacy of transfection in MCF-7 cells, CD BioSciences provides pre-optimized high-efficiency transfection reagent kits, specifically designed to facilitate efficient transfection.
